Key Drivers
- Strong gross margins
- Large operating losses
- Significant cash burn
AIAI Summary
HeartFlow has moved from a pre-commercial story to a revenue‑growth, high‑gross‑margin commercial play—driven by Aetna/payer wins that can unlock utilization upside—but the key actionable risk is whether management can convert payer coverage into sustained site adoption and operating‑cash‑flow improvement fast enough to avoid dilution given rich valuation and ongoing cash burn.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong gross margins
- •Large operating losses
- •Significant cash burn
HTFL has a strong liquidity and product-level margin profile but is loss-making with substantial cash burn and a rich valuation that elevates execution risk.
Price Behavior
Key Price Behavior Insights:
- •Modest upside
- •Rapid rebound
- •Elevated volatility
Over the last month HTFL shows a modest ~3–4% gain after a steep intraperiod drop to $20.49 and a rapid rebound into $25–26, leaving near-term resistance around $26.00 and support near $20.50 while momentum remains mixed and volatility elevated.
Steep drop to $20.49 then quick recovery into the $25–26 area indicating short-term volatile buying
Sentiment & News
Key News Insights:
- •Revenue acceleration
- •Clinical expansion
- •Institutional buying
HeartFlow reported robust commercial momentum with Q4 revenue up 40% to $49.1M, FY25 >$176M and 2026 guidance for ~25% revenue growth to $218–222M alongside expanding clinical programs and new institutional stakes.
If HeartFlow executes on product, margin and registry milestones, this momentum should support a positive re-rating driven by stronger commercial adoption and evidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings